RayzeBio Stock

rayzebio.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $397.75MM

RayzeBio develops novel peptide mimetic binders to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter.

Register To Buy and Sell Shares

For more details on financing and valuation for RayzeBio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access RayzeBio’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like RayzeBio.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

RayzeBio investors also invested in these private companies


Management Team

Ken Song, MD
President & Chief Executive Officer
Susan Moran, MD, MSCE
Chief Medical Officer
Arvind Kush
Chief Financial Officer
Kimberly Ma, MS
Senior Vice President, Clinical Operations
Eric Cischoff
Senior Vice President, Development and Operations
Aubrey Haddach, JD
General Counsel & Secretary
Abhi Bhat, PhD
Senior Vice President Chemistry, Head of Discovery
Nicholas Smith, PhD
Senior Vice President, Chemistry Innovation
Gary G. Li, PhD
Senior Vice President, Biology & Translational Medicine

Board Members

Bong Koh
Maha Katabi
Sofinnova Investments
Aaron Kantoff
Investment Partner
Aaron Royston
venBio Partners
Jerel Davis
Versant Ventures
Mike Dybbs
Samsara Capital

News Highlights

With fresh $160M, RayzeBio plots sprint through the clinic for lead radiopharmaceutical program — building on Novartis' success
Ever since its launch in 2020, RayzeBio has talked at length about building a platform company to fulfill the potential that radiopharmaceuticals hold — with seven active programs to boast. But it’s stayed mum about what those programs actually are, instead sticking to updates about new funding, hires or partnerships.
Updated on: Apr 22, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.